Translational Research Institute (TRI)

Partnering for better health to deliver innovative and life-changing therapeutics and treatments.

TRI Logo_newThe Translational Research Institute (TRI) brings four of the country's pinnacle research facilities together with a strong focus on translating the findings of basic biomedical research into better patient outcomes.

A joint venture between The University of Queensland Diamantina Institute, Queensland University of Technology’s Institute of Health and Biomedical Innovation, Mater Research and the Princess Alexandra Hospital’s Centres for Health Research, the TRI was established in 2013 with $354 million in funding provided by the Australian and Queensland Governments, The Atlantic Philanthropies, UQ and QUT.

The Institute is the culmination of the collective vision of 2006 Australian of the Year Professor Ian Frazer and Professor Derek Hart, former Director of Mater Research, together with clinicians and scientists from the Diamantina Health Partners, an integrated health sciences centre.

An Australian first, the Institute allows biopharmaceuticals and treatments to be discovered, produced, clinically tested and manufactured in a single location.

Researchers at the TRI aim to discover and develop new treatments and therapies to improve and benefit the health of people worldwide.